# Lung Cancer Screening with Low-Dose CT

## Overview

Lung cancer is the leading cause of cancer death in the United States, accounting for approximately 25% of all cancer mortality. The prognosis depends heavily on stage at diagnosis: five-year survival is 65% for localized disease but only 9% for distant metastatic disease. Low-dose computed tomography (LDCT) screening has been shown to reduce lung cancer mortality by 20 to 24% in high-risk populations, making early detection through screening one of the most impactful interventions available. The family physician's role encompasses identifying eligible patients, conducting the required shared decision-making visit, ordering and interpreting screening results, managing incidental findings, and integrating smoking cessation efforts into the screening process.

## Pathophysiology and Epidemiology

Lung cancer is histologically divided into non-small cell lung cancer, which accounts for approximately 85% of cases (including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma), and small cell lung cancer, which comprises the remaining 15%. Tobacco smoking is responsible for 80 to 90% of lung cancers and remains the dominant risk factor. Additional risk factors include radon exposure, asbestos, occupational carcinogens, family history of lung cancer, COPD, and prior chest radiation therapy.

## USPSTF Screening Criteria (2021)

### Eligibility

The USPSTF recommends annual LDCT screening for adults aged 50 to 80 who have a 20-pack-year or greater smoking history and currently smoke or quit within the past 15 years. Patients must be able and willing to undergo curative treatment if cancer is detected, as the benefit of screening depends on the ability to act on findings.

### Discontinuation Criteria

Screening should be discontinued when a patient has not smoked for 15 years, when a health problem develops that substantially limits life expectancy or the ability to undergo curative lung surgery, or when the patient exceeds age 80.

### Changes from 2013 Recommendation

The 2021 update lowered the eligible age from 55 to 50 and the pack-year threshold from 30 to 20. These changes expanded eligibility to approximately 14.5 million adults and importantly improved equity, as the revised criteria include more women and racial minorities who were previously excluded despite bearing a substantial burden of lung cancer.

## Shared Decision-Making Visit

### Required Components (CMS Mandate for Reimbursement)

CMS requires a documented shared decision-making visit before lung cancer screening will be reimbursed. The visit must include determination of eligibility through verification of age and smoking history, use of a decision aid that covers benefits, harms, and limitations of screening, smoking cessation counseling for current smokers, documentation of the shared decision-making discussion, and an order for LDCT at a designated screening center.

### Discussion Points

The benefits discussion should reference the NLST, which demonstrated a 20% relative reduction in lung cancer mortality, and the NELSON trial, which showed a 24% reduction. Early detection shifts stage at diagnosis toward more treatable disease. Harms include false-positive findings (approximately 25% of screens will have suspicious findings, most of which turn out to be benign), radiation exposure (1.5 mSv per LDCT compared to 7 mSv for a standard diagnostic CT), incidental findings requiring further workup, patient anxiety, and invasive procedures performed for benign lesions. The number needed to screen is approximately 320 people screened over three years to prevent one lung cancer death.

## Lung-RADS Reporting System

### Categories

Lung-RADS provides a standardized framework for reporting LDCT results and guiding follow-up. Category 1 (negative) indicates no nodules or definitively benign findings, and the patient continues annual screening. Category 2 (benign) identifies nodules with benign characteristics such as calcification or perifissural location, also warranting continued annual screening. Category 3 (probably benign) includes solid nodules measuring 6 to 8 mm or part-solid nodules with less than 6 mm solid component, requiring a six-month follow-up LDCT. Category 4A (suspicious) covers solid nodules 8 to 15 mm or growing nodules, prompting a three-month follow-up LDCT or PET/CT. Category 4B (very suspicious) applies to solid nodules 15 mm or larger or those with highly suspicious features, necessitating diagnostic CT with or without contrast, PET/CT, or tissue sampling. Category S (other) flags clinically significant findings unrelated to lung cancer.

| Lung-RADS Category | Description | Findings | Recommended Action |
|--------------------|-------------|----------|-------------------|
| 1 (Negative) | No nodules | No nodules or definitively benign | Continue annual LDCT |
| 2 (Benign) | Benign appearance | Calcified nodules, perifissural nodules | Continue annual LDCT |
| 3 (Probably Benign) | Low suspicion | Solid 6-8 mm; part-solid <6 mm solid | 6-month follow-up LDCT |
| 4A (Suspicious) | Moderate suspicion | Solid 8-15 mm or growing nodule | 3-month LDCT or PET/CT |
| 4B (Very Suspicious) | High suspicion | Solid ≥15 mm or highly suspicious features | Diagnostic CT, PET/CT, or biopsy |
| S (Other) | Significant non-cancer | Clinically significant incidental findings | Appropriate workup as indicated |

### Nodule Management

Different nodule types require different management approaches. Sub-solid or ground-glass nodules tend to be slower growing, often representing the adenocarcinoma spectrum, and can be followed with longer intervals. Solid nodules are managed based on size and growth kinetics. For part-solid nodules, the size of the solid component drives management decisions. A volume doubling time of less than 400 days is suggestive of malignancy.

## Incidental Findings

LDCT frequently reveals findings unrelated to lung cancer. Coronary artery calcification is detected in approximately 50% of screening CTs and correlates with cardiovascular risk, potentially providing the first opportunity to address CV prevention. Emphysema discovered incidentally may prompt a COPD workup and management discussion. Other common incidental findings include mediastinal lymphadenopathy, thyroid nodules, adrenal masses, and vertebral compression fractures. Establishing practice-level protocols for managing common incidental findings helps avoid unnecessary workups while ensuring clinically important findings are not ignored.

## Smoking Cessation Integration

The lung cancer screening visit represents a "teachable moment" for smoking cessation counseling. Paradoxically, a normal LDCT result can sometimes reduce a patient's motivation to quit by creating a false sense of security. An abnormal LDCT, on the other hand, tends to increase cessation rates. Pharmacotherapy should be offered at every screening visit, including varenicline, bupropion, and NRT. Screening should continue for current smokers alongside concurrent cessation efforts, not as a substitute for quitting.

## Implementation in Primary Care

Identifying eligible patients is the critical first step, and EHR-based clinical decision support can help, though smoking history documentation in medical records is often incomplete. Systematic identification through health maintenance reminders increases screening rates. Screening should be performed at ACR-designated lung cancer screening centers to ensure quality and standardized reporting. Nurse navigators improve adherence to follow-up imaging. Currently, fewer than 6% of eligible patients are being screened nationally, making lung cancer screening the USPSTF recommendation with the worst uptake of any A or B grade recommendation.

<image>A decision flowchart for lung cancer screening starting with eligibility assessment (age, pack-years, quit status), moving through shared decision-making, LDCT ordering, Lung-RADS classification of results, and follow-up actions for each Lung-RADS category. Use color-coding from green (continue annual screening) through yellow (short-interval follow-up) to red (tissue sampling/PET). Include a sidebar showing the required elements of the shared decision-making visit for CMS reimbursement.</image>

<image>A medical illustration showing cross-sectional CT images of lungs with examples of different Lung-RADS categories: a benign calcified granuloma (Category 2), a small solid nodule requiring follow-up (Category 3), a suspicious spiculated nodule (Category 4A), and a large mass with mediastinal lymphadenopathy (Category 4B). Label key imaging features (calcification, ground glass opacity, spiculation, size measurements) that help distinguish benign from malignant nodules.</image>

<image>A bar chart comparing lung cancer screening eligibility under the 2013 versus 2021 USPSTF criteria, broken down by sex, race/ethnicity, and age group. Show the expanded population now eligible under the updated criteria and highlight the improved equity in screening access for women, Black, and Hispanic populations. Include the estimated number of additional lung cancer deaths preventable under the new criteria.</image>

## Clinical Pearls

Documenting smoking history in pack-years at every visit is the single most important step for identifying screening-eligible patients and is the most commonly cited barrier to implementation. Lung cancer screening has the worst uptake of any USPSTF A or B recommendation, with fewer than 6% of eligible individuals screened, making systematic identification and proactive outreach essential. A normal LDCT does not eliminate lung cancer risk, and annual screening must continue as long as the patient meets eligibility criteria. The shared decision-making visit is a CMS billing requirement, not an optional conversation, and using a standardized decision aid streamlines the process. Incidental coronary artery calcification on LDCT may represent the first clinical opportunity to address cardiovascular risk in a patient. False-positive rates decrease with subsequent annual screening rounds as prevalent findings are sorted out. Chest X-ray and sputum cytology should never be used for lung cancer screening, as neither modality reduces mortality. Every screening visit should include aggressive smoking cessation counseling and pharmacotherapy offers.

## References

- USPSTF Lung Cancer Screening Recommendation (2021)
- National Lung Screening Trial (NLST): Aberle et al., NEJM 2011
- NELSON Trial: de Koning et al., NEJM 2020
- ACR Lung-RADS Assessment Categories v2022
- Fleischner Society Guidelines for Incidental Pulmonary Nodules (2017)
- CMS Decision Memo for Screening for Lung Cancer with LDCT
- Jonas DE et al. Screening for Lung Cancer: Updated Evidence Report. JAMA 2021